Increasing prevalence of obesity combined with longevity will produce an epidemic of Type 2 (non-insulindependent) diabetes in the next 20 years. This disease is associated with defects in insulin secretion, specifically abnormalities of insulin secretory kinetics and pancreatic β-cell glucose responsiveness. Mechanisms underlying β-cell dysfunction include glucose toxicity, lipotoxicity and β-cell hyperactivity. Defects at various sites in β-cell signal transduction pathways contribute, but no single lesion can account for the common form of Type 2 diabetes. Recent studies highlight diverse β-cell actions of GLP-1 (glucagonlike peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These intestinal hormones target the β-cell to stimulate glucose-dependent insulin secretion through activation of protein kinase A and associated pathways. Both increase gene expression and proinsulin biosynthesis, protect against apoptosis and stimulate replication/neogenesis of β-cells. Incretin hormones therefore represent an exciting future multi-action solution to correct β-cell defect in Type 2 diabetes.
Introduction
The physiological role of pancreatic β-cells is to sense an increase in the circulating concentration of glucose (and other nutrients) after feeding and to secrete an appropriate amount of insulin into the blood to ensure prompt and efficient metabolic disposal [1] . Regulation of this process is further aided by the actions of incretin hormones and neural pathways that make up the enteroinsular axis [2] . Defects in nutrient regulation of insulin secretion and resistance to the cellular actions of insulin are both key to the development of Type 2 (noninsulin-dependent) diabetes. The purpose of the present article is to briefly discuss the nature of the β-cell defect in Type 2 diabetes, to consider short-comings of current drug treatments and to review possible future solutions offered by a new antidiabetic drug class, namely stable incretin hormone analogues [3] .
Diabetes
There are two types of diabetes which together affect up to 3-7% of the population in Western societies. Type 1 (insulindependent) diabetes, caused by autoimmune destruction of pancreatic β-cells, usually develops before adulthood and requires insulin injection [4] . Type 2 diabetes more often manifests in later life and accounts for approx. 95% of all cases. It is commonly treated through diet and prescription of drugs to increase the secretion and action of insulin [4] . Both forms of diabetes are becoming increasingly common and costs to annual healthcare budgets range from 10 to 14%. Worldwide, cases of diabetes are expected to reach epidemic proportions by 2025, with more than 300 million individuals being affected. This sharp increase partly reflects changes of diet and lifestyle in developing countries and the strong link of Type 2 diabetes with obesity and increasing age. Thus, in Western societies, the aged population is increasing and obesity rates have almost tripled over the past 20 years. Poor diabetes control results in many complications, including vascular disease, kidney failure, blindness, lower leg amputation, impotence and mental disease [4] . Accordingly, the search for new and improved treatments for diabetes represents an important ongoing challenge [5] .
Current treatments for Type 2 diabetes
Type 2 diabetes is associated with two key defects, namely (i) impairment of pancreatic β-cell function and (ii) insulin resistance at target tissues such as muscle, liver and adipose tissue. The ideal treatment for Type 2 diabetes should preferably tackle both of these defects. Dietary management is important, as reducing adiposity will enhance insulin action and glucose disposal [6] . However, moderate or severe hyperglycaemia invariably requires drug intervention [5, 7, 8] . Current therapies act by enhancing insulin secretion (sulfonylureas; meglitinides) or reducing insulin resistance (biguanides; thiazolidinediones) [5, 7, 8] . Additional options include α-glucosidase inhibitors (acarbose; miglitol) to reduce the rate of carbohydrate digestion and absorption. Unfortunately, all of the available agents are limited in efficacy by the progressive deterioration of β-cell function that occurs throughout the natural history of Type 2 diabetes. Thus a future treatment that could boost insulin secretion and prevent or reverse this gradual β-cell decline would be highly beneficial.
Regulation of pancreatic β-cell and diabetes
The inability of pancreatic β-cells to recognize and respond to glucose is a hallmark of Type 2 diabetes. Glucose is not only the primary regulator of β-cell function but dictates the insulinotropic potency of many other secretogogues [9] . Signals generated by these agents are normally integrated at the level of the β-cell through a complex network of second messenger and effector pathways. For glucose stimulation of insulin secretion, this primarily involves the steps of glucose transport, metabolism, ATP production, K-ATP channel closure, membrane depolarization and influx of Ca 2+ through voltage-dependent calcium channels. Elevated Ca 2+ then triggers exocytosis. Interestingly, the sulfonylureas and meglitinide drugs act by binding to the sulfonylurea receptor component of K-ATP channels to decrease K + permeability and trigger Ca 2+ entry [10, 11] . However, these agents do not recapitulate the less well-understood augmentation pathways activated through β-cell glucose metabolism [9, 12, 13] . As a result, they do not replenish insulin stores and can lead to eventual desensitization and/or exhaustion of β-cells [14] . Elevation of intracellular Ca 2+ also activates various enzymes such as adenylate cyclase (producing cAMP) and phospholipase C (producing diacylglycerol and inositol 1,4,5-trisphosphate). Such enzyme systems are also activated by specific receptors for hormonal and neural components of the enteroinsular axis, leading to activation of PKA (protein kinase A) and PKC that promote protein phosphorylation and sensitization of the secretory machinery to action of secretagogue action of Ca 2+ . From the above, it follows that a lesion at any one locus in the sequence of events linking glucose recognition to discharge of insulin by exocytosis might contribute to defective insulin secretion. This has fuelled an extensive search for mutations in the key islet regulatory genes (encoding enzymes, ion channels etc.) in populations with Type 2 diabetes [15] . Such a research has unveiled a number of previously unidentified and rare forms of MODY (maturity-onset diabetes of the young) that represent 1-2% diabetes and result from inherited mutations in genes for glucokinase or different transcription factors affecting β-cells [15] (Table 1 , part a). However, simple mutation in one, or indeed a small number, of genes does not account for β-cell dysfunction in common form of Type 2 diabetes. Probably more important in this regard is the impact of environmental disturbances including glucose toxicity, lipotoxicity and β-cell hyperactivity [16] . Thus many studies have shown that these features associated with diabetes adversely affect β-cell function.
Recent research has highlighted diverse actions of incretin hormones, GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), to positively affect β-cell function [3] . These intestinal hormones target the β-cell to stimulate glucose-dependent insulin secretion through activation of PKA and associated pathways. Both increased gene expression and proinsulin biosynthesis protect against apoptosis and stimulate replication/neogenesis of β-cells. Incretin hormones therefore represent a multisite means 
The incretin hormones
The concept of the 'enteroinsular axis' was conceived to describe all 'gut factors' that contribute to enhanced insulin secretion following the ingestion of a meal [17] . It was suggested later that the axis comprised nutrient, neural and hormonal components. Creutzfeldt [2] laid down the two key criteria required for the classification of incretin hormones. First, an incretin must be released in response to nutrients, particularly carbohydrates, and secondly, it must stimulate insulin secretion at physiological concentrations. The two main incretin hormones, GLP-1 and GIP, are now well established [3] . These peptide hormones have surpassed expectations as antihyperglycaemic agents because they not only have potent insulin-releasing actions, but they also lower blood glucose by other pancreatic and extrapancreatic actions. 
Incretin hormone actions in the pancreatic β-cell
Incretin hormones act in several distinct ways to lower blood glucose, the most notable being potent stimulation of insulin secretion ( Figure 1 ). Insulin release stimulated by the incretin hormones occurs in a glucose-dependent manner. This serves to minimize the risk of hypoglycaemia [18, 19] , a difficulty faced by insulin-releasing sulfonylureas and meglitinides presently used for Type 2 diabetes therapy [5] . This particular characteristic has been fundamental to the recent therapeutic interest in both GLP-1 and GIP. As shown in Table 1 (part b), the incretin hormones have been shown to exhibit several other actions, including inhibition hepatic glucose production [20, 21] , decrease of insulin clearance [22] and promotion of glucose uptake [23, 24] in peripheral tissues, which may further contribute to glucose lowering in Type 2 diabetic patients. The antidiabetic profile of incretin hormones has been further raised by mounting evidence that suggests that both GLP-1 and GIP enhance the growth, differentiation, proliferation and survival of pancreatic β-cells [3] (Table 1, part b) . Thus a large number of reports indicate that the incretin hormones are involved in modulating pancreatic β-cell mass. GLP-1 and GIP can increase the overall mass of β-cells by (i) reducing β-cell apoptosis, (ii) increasing islet cell proliferation and (iii) causing differentiation of cells to a β-cell phenotype. GLP-1 agonists have demonstrated antiapoptotic effects on islets and β-cells in animal models of Type 1 and Type 2 diabetes [25] [26] [27] . GIP has also been shown to inhibit β-cell apoptosis [28] [29] [30] . In vitro experiments that indicated that GLP-1 stimulates islet cell proliferation [31, 32] are corroborated by several in vivo studies [33] [34] [35] . The proliferative effect of GLP-1 on β-cells may partly be attributed to the stimulation of insulin gene transcription and insulin biosynthesis [36] . GIP has been shown to stimulate β-cell proliferation synergistically with glucose in the islet INS-1 cell line [28, 37] . Findings in our laboratory and others indicate that GLP-1 promotes the differentiation of a pancreatic ductal cell line to an endocrine cell phenotype [38, 39] . Cells differentiated using GLP-1 express islet hormones, the glucose transporter Glut-2 and are capable of insulin secretion [38, 39] . Evidence also indicates that GIP may help promote differentiation of embryonic stem cells to a β-cell phenotype [40] . The effects of the incretin hormones to stimulate cellular proliferation, inhibit apoptosis and promote differentiation of insulin-producing cells indicate that their therapeutic use could slow β-cell decline and avoid the risk of β-cell exhaustion.
Development of DPPIV (dipeptidyl peptidase IV)-resistant incretin analogues with enhanced potency
One of the major obstacles encountered in the therapeutic development of GLP-1 and GIP has been their rapid degradation in the circulation, which chiefly occurs as a result of the enzyme, DPPIV (EC 3.4.14.5) [41] . DPPIV cleaves Nterminal dipeptides from both GLP-1 (His 7 -Ala 8 ) and GIP (Tyr 1 -Ala 2 ) (Figure 2 ). Truncated metabolites GLP-1-(9-36)-amide and GIP-(3-42) lack insulinotropic activity and may act at high concentrations antagonistically on their respective receptors.
DPPIV is an enzyme that prefers an alanine, proline or hydroxyproline residue in the penultimate N-terminal position. GLP-1 and GIP possess similar N-terminal regions, i.e. His 7 -Ala 8 -Glu 9 -and Tyr 1 -Ala 2 -Glu 3 -respectively (Figure 2 ), which explains their susceptibility to DPPIV degradation. Three different types of structural modifications have been investigated to safeguard GLP-1 and GIP against DPPIV degradation. The first involves, extension of the N-terminal His 7 and Tyr 1 positions of GLP-1 and GIP respectively by various chemical modifications [42, 43] . The second involves amino acid substitution at Ala 8 [44] and Glu 9 [45, 46] of GLP-1, and at Ala 2 [47] and Glu 3 [48, 49] of GIP respectively. Finally, GLP-1 and GIP have been acylated with long-or short-chain fatty acids to promote longer biological action through albumin binding [50, 51] .
All three types of modification have led to the generation of GLP-1 or GIP analogues with reduced or even complete resistance to degradation by DPPIV. This attribute appears to be a relatively straightforward to attain. However, these modifications have variable effects on biological activity producing analogues with enhanced, neutral or inferior potency (detailed in our earlier review [3] ). On the whole, the bioactivity of GIP is not as sensitive as GLP-1 to compromise when structural changes are introduced to impart DPPIV stability. Examples of DPPIV-resistant analogues of GLP-1 and GIP which possess enhanced biological activity are (Val 8 )GLP-1 and N-acetyl GIP respectively [42, 43] . Administration of (Val 8 )GLP-1 for 3 weeks in ob/ob diabetic mice led to improved glucose tolerance, reduced the glycaemic excursion after feeding, increased the plasma insulin response to glucose and feeding, and improved insulin sensitivity [33] . Furthermore, (Val 8 )GLP-1 treatment increased average islet area by 20% without changing the number of islets. Similar antidiabetic effects were observed in ob/ob mice with longerterm administration of stable N-acetyl GIP analogues modified at lysine residues to carry palmitate fatty acid [52, 53] . Notably, β-cell function was much improved, indicating that stable GIP analogues can overcome any sluggish response to native GIP that may arise as a consequence of the generalized β-cell defect in Type 2 diabetes.
Exendin-4-(1-39) (also known as exenatide or Byetta) is a DPPIV-resistant GLP-1 receptor agonist isolated from the saliva of the Gila Monster lizard, which has recently been licensed in U.S.A. for the treatment of Type 2 diabetes [3] . Other long-acting GLP-1 analogues, such as liraglutide (NN2211) or LY307161, are in late phase clinical trials. Such analogues have been acylated, which facilitates binding with plasma proteins to circumvent renal filtration and making them suitable for once-or twice-daily administration [3] .
The search for DPPIV-resistant analogues of GIP has led to the discovery of a specific GIP-receptor antagonist, (Pro 3 )GIP, which offers potential as a therapeutic agent. Thus daily administration of (Pro 3 )GIP resulted in marked improvement of diabetes control in ob/ob mice by substantially improving insulin sensitivity [54] . This effect was associated with β-cell sparing as evidenced by lowering of insulin output, improvement of β-cell glucose responsiveness and correction of β-cell mass. Accordingly, GIP antagonists as well as agonists have beneficial effects on β-cell function in diabetes mediated by either promoting the secretion or effectiveness of insulin respectively.
Conclusion
Dysfunction and decline of pancreatic β-cells are key features of Type 2 diabetes. Mechanisms underlying β-cell defects are at present poorly understood and currently available antidiabetic drugs targeting insulin secretion are far from ideal in their action. New research suggests that emerging incretin hormone therapies could significantly counter β-cell decline and failing insulin secretion, representing a potential solution to a more effective means of treating Type 2 diabetes.
